Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals, has secured exclusive multi-regional rights to Aumolertinib from Hansoh Pharma. This agreement covers development and commercialization across the Middle East, Africa, Southeast & South Asia, Australia, New Zealand, Russia/CIS, and selected Caribbean countries. Aumolertinib is a third-generation EGFR-TKI for treating non-small cell lung cancer (NSCLC). Hansoh Pharma will receive an upfront payment and potential milestone payments.
Aumolertinib Licensing Agreement
Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), has entered into an exclusive license, collaboration, and distribution agreement with Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma) for Aumolertinib. Aumolertinib is a third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) used in the treatment of non-small cell lung cancer (NSCLC).
Territorial Rights and Financial Details
Under the terms of the agreement, Glenmark gains exclusive rights to develop and commercialize Aumolertinib across its licensed territories, including the Middle East and Africa, Southeast & South Asia, Australia, New Zealand, Russia/CIS, and selected Caribbean countries. Hansoh Pharma will receive an upfront payment described as a low double-digit million USD, followed by potential regulatory and commercial milestone payments that could cumulate to over US$1 billion, plus tiered royalties on net sales in the licensed territories.
Executive Commentary
According to Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals Ltd., Aumolertinib is a strategic addition that strengthens their near-term commercial pipeline and enhances their ability to serve patients with EGFR-mutated lung cancer. He stated that this collaboration reinforces their disciplined approach to expanding their innovative portfolio and widening access to advanced cancer care across key markets.
About Aumolertinib
Aumolertinib, marketed as Ameile in China and Aumseqa® in the United Kingdom and Europe, has received marketing authorization from the UK MHRA as a monotherapy. It is indicated for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) with activating epidermal growth factor receptor (“EGFR”) mutations, and for treating adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. It has four approvals in China for second-line T790M mutation, first-line NSCLC EGFR mutated, unresectable Stage III post-chemoradiotherapy, and adjuvant Stage II-IIIB NSCLC.
In March 2020, it was approved for treating patients with locally advanced or metastatic NSCLC with T790M mutation after EGFR-TKI therapy. In December 2021, it was approved as first-line treatment for adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutation positive. In March 2025, it was approved for treating patients with locally advanced, unresectable NSCLC whose disease has not progressed following platinum-based chemoradiotherapy whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutations. In May 2025, it was approved for the adjuvant treatment of adult patients with stage II to IIIB NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations and who have undergone tumor resection. In June 2025, Aumolertinib (trade name Aumseqa) was approved by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom (MHRA).
Source: BSE
